Xencor Inc.: Current Biotech Uncertainty Is An Opportunity Seeking Alpha Previous drugs such as Rituximab or Rituxan (Biogen (BIIB) and Roche/Genentech) have also targeted B-cells in RA but have safety issues due to excessive B-cell depletion. However, it is important to note that Rituxan did ~$7.5bn in sales in 2013 across ... |
